What is the role of pertuzumab in the treatment of HER2-positive breast cancer?

Updated: May 14, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Karl S Roth, MD  more...
  • Print
Answer

Answer

Baselga et al reported that adding pertuzumab to traditional therapy with trastuzumab and docetaxel improved disease-free survival time in patients with HER2- positive metastatic breast cancer. [16] Pertuzumab gained approvals for neoadjuvant treatment in combination with trastuzumab and docetaxel for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer. [17]

Based on the findings from the APHINITY trial, pertuzumab was also approved for the use in combination with trastuzumab and chemotherapy for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. In the multicenter, double-blind, placebo-controlled study, 4804 patients with HER2-positive early breast cancer were randomized to receive pertuzumab or placebo, in combination with adjuvant trastuzumab and chemotherapy.

At a median follow-up of 45.4 months, 7.1% patients in the pertuzumab group had developed invasive breast cancer, compared to 8.7% patients in the placebo group. At 3 years, an estimated 94.1% of patients in the pertuzumab group were free of invasive breast cancer, compared to 93.2% of patients in the placebo group. [18]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!